| FORM
3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act
of 1940
|
| OMB APPROVAL |
| OMB Number: |
3235-0104 |
| Expires: |
December 31, 2014 |
| Estimated average burden |
| hours per response: |
0.5 |
|
|
1. Name and Address of Reporting Person
*
| DA32 LIFE SCIENCE TECH ACQUISITION CORP |
| 345 PARK AVENUE SOUTH, 12TH FLOOR |
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year)
07/27/2021
|
3. Issuer Name
and
Ticker or Trading Symbol
DA32 Life Science Tech Acquisition Corp.
[
DALS
]
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| X |
Director |
|
10% Owner |
|
Officer (give title below) |
|
Other (specify below) |
|
|
5. If Amendment, Date of Original Filed
(Month/Day/Year)
|
6. Individual or Joint/Group Filing (Check
Applicable Line)
| X |
Form filed by One Reporting Person |
|
Form filed by More than One Reporting
Person |
|
| Table I - Non-Derivative Securities Beneficially Owned |
|---|
| 1. Title of Security (Instr.
4)
|
2.
Amount of Securities Beneficially Owned (Instr.
4)
|
3. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
4. Nature of Indirect Beneficial Ownership (Instr.
5)
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
|
|---|
| 1. Title of Derivative Security (Instr.
4)
|
2. Date Exercisable and Expiration Date
(Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr.
4)
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form: Direct (D) or Indirect (I) (Instr.
5)
|
6. Nature of Indirect Beneficial Ownership (Instr.
5)
|
| Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Class B Common Stock
|
|
|
Class A Common Stock
|
30,000
|
(1)
|
D
|
|
| Explanation of Responses: |
|
| Remarks: |
| See Exhibit 24.1 - Power of Attorney. |
|
/s/ Henrikki Harsu, Attorney-in-Fact |
07/27/2021 |
|
** Signature of Reporting Person |
Date |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
| * If the form is filed by more than one reporting person,
see
Instruction
4
(b)(v). |
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure. |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |
POWER OF ATTORNEY
The undersigned constitutes and appoints Joel Rubinstein, Daniel Nussen,
Henrikki Harsu, Audrey Bae, Alexis Ko and Lane Ransom or any of them acting
singly, as the undersigned's true and lawful attorneys-in-fact and agents, with
full power of substitution and resubstitution, for the undersigned and in the
undersigned's name, place and stead, to:
1. prepare, sign, and submit to the Securities and Exchange
Commission (the "SEC") on its Electronic Data Gathering, Analysis, and Retrieval
("EDGAR") Filer Management website a Form ID application, including any
amendments and exhibits thereto, and any other related documents as may be
necessary or appropriate, to obtain from the SEC access codes to permit filing
on the SEC's EDGAR system, granting unto said attorneys-in-fact and agents, and
each of them, full power and authority to do and perform each act and thing
requisite and necessary to be done as required by any rule or regulation of the
SEC and the EDGAR Filer Manual as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof; and
2. sign any and all SEC statements of beneficial ownership of
securities of DA32 Life Science Tech Acquisition Corp. (the "Company") on
Schedule 13D as required under Section 13 and Forms 3, 4 and 5 as required under
Section 16(a) of the Securities Exchange Act of 1934, as amended, and any
amendments thereto, and to file the same with all exhibits thereto, and other
documents in connection therewith, with the SEC, the Company and any stock
exchange on which any of the Company's securities are listed, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each act and thing requisite and necessary to be done under said
Section 13 and Section 16(a), as fully and to all intents and purposes as the
undersigned might or could do in person, hereby ratifying and confirming all
that said attorneys-in-fact and agents, and each of them, may lawfully do or
cause to be done by virtue hereof.
A copy of this power of attorney shall be filed with the SEC. The
authorization set forth above shall continue in full force and effect until the
undersigned revokes such authorization by written instructions to the attorneys-
in-fact.
The authority granted hereby shall in no event be deemed to impose or
create any duty on behalf of the attorneys-in-fact with respect to the
undersigned's obligations to file a Form ID, Schedule 13Ds and Forms 3, 4 and 5
with the SEC.
Dated: June 7, 2021
/s/ Nicolas H Roelofs
-------------------------------
Nicolas H Roelofs
Tweet
Share
E-mail
